Possible reasons are i) investigated proteins not meeting the requirements to support clinical decisions (e.g. delayed detection of neuronal injury by S100B67 and NfL68 limiting their value in supporting time-sensitive treatment decisions in the acute phase of stroke) and ii) lack of studies supporting high-level evidence of protein biomarkers (e.g. a randomized controlled trial for an NT-proBNP-based decision on secondary stroke prevention). The gene discussed is NPPB; the disease is stroke disorder.